Pharmaceuticals, Biotechnology and Life Sciences
Don't spend too much on your repeated translations.
Cut costs with Vikler Media. Visit: media.vikler.net
Secarna to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases.
Bristol Myers Squibb and Bain Capital announced Monday the creation of a new independent biopharmaceutical company, called NewCo, which will be focused on developing new therapies for autoimmune diseases that...
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast density this Christmas. Dense breast tissue is a relatively unknown but common breast cancer risk factor, which additionally makes it...
Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in...
Over-65s across the UK are set to benefit from potentially life-changing new treatment options for conditions like cancer and cardiovascular...
Following the submission in December 2025, USFDA has accepted Dr. Reddy’s 351(k) Biologics License Application (BLA) for Proposed Interchangeable biosimilar…
Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio…
Meta-analysis showed an association between the frequency of clinician-administered assessments and magnitude of placebo response in generalized anxiety disorder (GAD)…
HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and…
– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment…
– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death…
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond…
Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full…
U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908…
Findings unveiled at the University of Florida Scientific Kratom Symposium highlight encouraging results for adult use of low-dose proprietary kratom…
